Skip Navigation


Cardiovascular Research Advance Access first published online on August 14, 2009
This version [Corrected Proof] published online on September 4, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp282
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
85/2/339    most recent
cvp282v3
cvp282v2
cvp282v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Tsukamoto, O.
Right arrow Articles by Kitakaze, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsukamoto, O.
Right arrow Articles by Kitakaze, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org.

Functional alterations of cardiac proteasomes under physiological and pathological conditions

Osamu Tsukamoto1, Tetsuo Minamino2 and Masafumi Kitakaze1,*

1 Department of Cardiovascular Medicine, National Cardiovascular Center, Suita 565-8565, Japan
2 Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan

* Corresponding author. Tel: +81 6 6833 5012 Ext. 2225, Fax: +81 6 6836 1120, Email: kitakaze{at}zf6.so-net.ne.jp

The cardiac proteasome is a complex, heterogeneous, and dynamic organelle. Its function is regulated by its molecular organization, post-translational modifications, and associated partner proteins. Pressure overload, ischaemic heart disease, or genetic mutations in contractile proteins can cause heart failure, during which misfolded protein levels are elevated. At the same time, numerous interconnected signal transduction pathways are activated that may modulate any of the three proteasomal regulatory mechanisms mentioned above, resulting in functional changes in cardiac proteasomes. Many lines of evidence support the important role of the ubiquitin-proteasome system (UPS) in the development of heart diseases. Many researchers have focused on the UPS, applying new drug discovery methods not only in the field of cancer research but also in cardiovascular fields such as cardiac hypertrophy and ischaemic heart diseases. More understanding of UPS in the pathophysiology of heart diseases will lead to new routes for therapy.

KEYWORDS Proteasome regulation; Molecular organization; Post-translational modification; Associating partner protein; Heart failure

Time for primary review: 18 days

This article is part of the Spotlight Issue on: The Role of the Ubiquitin-Proteasome Pathway in Cardiovascular Disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
C. Depre, S. R. Powell, and X. Wang
The role of the ubiquitin-proteasome pathway in cardiovascular disease
Cardiovasc Res, January 15, 2010; 85(2): 251 - 252.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.